Both Odonate Therapeutics Inc. (NASDAQ:ODT) and Intec Pharma Ltd. (NASDAQ:NTEC) are each other’s competitor in the Biotechnology industry. Thus the compare of their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Odonate Therapeutics Inc.||N/A||0.00||88.96M||-3.63||0.00|
|Intec Pharma Ltd.||N/A||0.00||43.54M||-1.40||0.00|
Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Odonate Therapeutics Inc. and Intec Pharma Ltd.
Table 2 provides us Odonate Therapeutics Inc. and Intec Pharma Ltd.’s return on assets, return on equity and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Odonate Therapeutics Inc.||0.00%||-55.9%||-51.5%|
|Intec Pharma Ltd.||0.00%||0%||0%|
Insider and Institutional Ownership
The shares of both Odonate Therapeutics Inc. and Intec Pharma Ltd. are owned by institutional investors at 94.9% and 39.64% respectively. Odonate Therapeutics Inc.’s share held by insiders are 2.4%. Insiders Comparatively, held 11.81% of Intec Pharma Ltd. shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Odonate Therapeutics Inc.||9.61%||2.6%||4.29%||-17.99%||-38.07%||20.74%|
|Intec Pharma Ltd.||-5.95%||4.85%||37.69%||116.32%||34.75%||9.02%|
For the past year Odonate Therapeutics Inc.’s stock price has bigger growth than Intec Pharma Ltd.
Intec Pharma Ltd. beats on 4 of the 6 factors Odonate Therapeutics Inc.
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics to enhance the lives of patients with cancer in the United States. It is developing Tesetaxel, a novel chemotherapy agent that has completed Phase II clinical trials for patients with advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The companyÂ’s lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of ParkinsonÂ’s disease symptoms in advanced ParkinsonÂ’s disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.